Highlights JCR Pharmaceuticals Co., Ltd.

Equities

4552

JP3701000006

Market Closed - Japan Exchange Other stock markets 11:30:00 17/05/2024 am IST			5-day change	1st Jan Change
622 ^JPY	+0.97%		-22.15%	-46.93%

10/05	JCR Pharmaceuticals Co., Ltd. Announces Dividend for the Year Ended March 31, 2024, Payable on June 27, 2024	CI
25/04	JCR Pharmaceuticals Co., Ltd. Announces Management Changes, Effective as of June 26, 2024	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

JCR Pharmaceuticals Co., Ltd. Announces Dividend for the Year Ended March 31, 2024, Payable on June 27, 2024	10/05	CI
Final dividend	28/03	FA
US Fed Rate Outlook Catapults Japanese Shares to Fresh 52-Week Peak	21/03	MT
JCR Pharmaceuticals Achieves Neurodegenerative Treatment Research Milestone With Alexion	21/03	MT
JCR Pharmaceuticals Co., Ltd. Announces Achievement of Milestone Using J-Brain Cargo Technology for Neurodegenerative Disease in Research Collaboration with Alexion	19/03	CI
JCR Pharmaceuticals Co., Ltd. Presents Clinical Data on J-Brain Cargo®? to Deliver Medicines Across the Blood-Brain Barrier	14/02	CI
JCR Pharmaceuticals Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2024	09/02	CI
JCR Pharmaceuticals' Partner Takeda to Scrap Gene Therapy Collaboration	21/12	MT
JCR Pharmaceuticals Co., Ltd. and Takeda Pharmaceutical Co., Ltd. Announces Discontinuation of Gene Therapy Collaboration	20/12	CI
JCR Announces Research Collaboration, Option and License Agreement with Alexion on Discovery of Oligonucleotide Therapeutics Using J-Brain Cargo	20/12	CI
Modalis Therapeutics, JCR Pharmaceuticals Form Drug Delivery Research Partnership	13/12	MT
Modalis Therapeutics Corporation and JCR Pharmaceuticals Enter into Joint Research Agreement	13/12	CI
Japanese Shares Rebound on Wednesday, Boosted by Automotive Stocks	22/11	MT
JCR Pharmaceuticals' Fiscal H1 Attributable Profit Climbs on Increased Drug Sales	22/11	MT
JCR Pharmaceuticals Co., Ltd. Announces First Patient Dosed in a Global Phase I/II Clinical Trial of JR-441 for the Treatment of MPS IIIA	27/23/27	CI
JCR Pharmaceuticals Co., Ltd. Declares Interim Dividend for the Fiscal Year Ending March 31, 2024, Payable on December 8, 2023; Provides Dividend Guidance for the Fiscal Year Ending March 31, 2024	25/23/25	CI
JCR Pharmaceuticals Co., Ltd. Announces 52-Week Interim Data from its Global Phase I/II Study of JR-171 in Individuals with Mucopolysaccharidosis Type I (MPS I)	29/23/29	CI
MEDIPAL Holdings Corporation and JCR Pharmaceuticals Co., Ltd. Conclude Two Agreements on Mucopolysaccharidosis Type IIIB Treatment	28/23/28	CI
JCR Pharmaceuticals Co., Ltd. Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024	28/23/28	CI
Ex-dividend day for interim dividend	28/23/28	FA

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights JCR Pharmaceuticals Co., Ltd.

Equities

4552

JP3701000006

Highlights

Filters